|Bid||16.06 x N/A|
|Ask||16.07 x N/A|
|Day's Range||15.80 - 17.14|
|52 Week Range||15.80 - 27.88|
|Beta (5Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tilray is set to report its first quarter since closing a blockbuster tie-up deal with Aphria. Analysts expect it will be messy.
As talk of potential legislation to legalize cannabis in the U.S. continues, stocks of many Canadian growers have been volatile. In just the past month, shares of Tilray (NASDAQ: TLRY), Sundial Growers (NASDAQ: SNDL), and OrganiGram Holdings (NASDAQ: OGI) are down 30%, 20%, and 18%, respectively. Tilray CEO Irwin Simon did give an interview yesterday in which he discussed the future of the company and explained its position in preparation for potential U.S. legalization.
Tilray may be one of the top Canadian pot stocks to place your bets on right now. It has a presence in several countries including the U.S. and Europe and is rapidly improving profit margins. The post Tilray Stock: Should You Buy, Sell or Hold? appeared first on The Motley Fool Canada.